Trials / Recruiting
RecruitingNCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 780 (estimated)
- Sponsor
- Summit Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ivonescimab Injection | Subject will receive ivonescimab as an IV injection |
| BIOLOGICAL | Pembrolizumab Injection | Subject will receive Pembrolizumab as an IV injection |
Timeline
- Start date
- 2025-02-27
- Primary completion
- 2028-04-01
- Completion
- 2029-06-01
- First posted
- 2025-01-10
- Last updated
- 2026-02-24
Locations
202 sites across 16 countries: United States, Canada, China, France, Germany, Greece, Hungary, Italy, Japan, Mexico, Poland, Portugal, Romania, Serbia, Spain, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06767514. Inclusion in this directory is not an endorsement.